US Patent

US9662342 — Formulations of cyclophosphamide liquid concentrate

Formulation · Assigned to Auromedics Pharma LLC · Expires 2035-06-26 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of cyclophosphamide liquid concentrate that maintain high levels of cyclophosphamide content after storage for 18 or 24 months at 5°C.

USPTO Abstract

Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C.

Drugs covered by this patent

Patent Metadata

Patent number
US9662342
Jurisdiction
US
Classification
Formulation
Expires
2035-06-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Auromedics Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.